Bio-Path Holdings, Inc. (BPTH)
Stock Price:
$5.26 USD
1.17 (28.61%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $5.12 -0.14 (-2.66%) Oct 22, 7:59 PM
Key Info
| Market Cap |
19.42M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-10.00M |
| Shares Out |
3.69M |
| EPS (ttm) |
-2.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$5.26 |
| Previous Close |
$4.09 |
| Change ($) |
1.17 |
| Change (%) |
28.61% |
| Day's Open |
5.28 |
| Day's Range |
4.77 - 6.09 |
| Day's Volume |
49,211,664 |
| 52-Week Range |
2.92 - 12.86 |
More Stats
| Market Cap |
19.42M |
| Enterprise Value |
5.38M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
3.69M |
| Float |
3.49M |
| EPS (basic) |
-2.96 |
| EPS (diluted) |
-2.97 |
| FCF / Share |
-2.75 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10,747 |
| Short Ratio |
0.13 |
| Short % of Float |
0.31% |
| Beta |
2.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.95 |
| Revenue |
n/a |
| Operating Income |
-10.07M |
| Net Income |
-10.00M |
| Free Cash Flow |
-10.15M |
| Net Cash |
14.04M |
| Net Cash / Share |
3.80 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-34.17% |
| ROE |
-58.93% |
| ROIC |
-685.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
12.0
Current: $5.26
High
12.0
Target: 12.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | 0.04 | 0.01 | - | - | - | - | - | - |
| Revenue Growth | - | - | 184.62% | - | - | - | - | - | - | - |
| Gross Profit | - | - | 0.04 | 0.01 | - | - | - | - | - | - |
| Operating Income | -8.69 | -8.59 | -8.97 | -8.48 | -5.49 | -4.54 | -3.27 | -2.58 | -2.37 | -2.33 |
| Net Income | -8.60 | -8.58 | -7.02 | -6.75 | -5.47 | -4.52 | -3.27 | -2.58 | -2.36 | -2.08 |
| Shares Outstanding | 2.66 | 0.60 | 0.50 | 0.46 | 0.45 | 0.45 | 0.36 | 0.30 | 0.27 | 0.24 |
| Earnings Per Share | -3.24 | -14.38 | -15.99 | -14.60 | -12.00 | -10.00 | -10.00 | -8.00 | -8.00 | -8.00 |
| Operating Cash Flow | -8.36 | -6.12 | -7.96 | -8.15 | -5.01 | -3.82 | -2.31 | -1.99 | -1.15 | -1.15 |
| Capital Expenditures | - | -0.02 | -0.54 | -0.34 | - | -0.12 | - | - | - | - |
| Free Cash Flow | -8.36 | -6.14 | -8.50 | -8.49 | -5.01 | -3.94 | -2.31 | -1.99 | -1.15 | -1.15 |
| Cash & Equivalents | 20.43 | 1.00 | 5.97 | 9.38 | 8.85 | 13.86 | 3.55 | 0.53 | 0.95 | 0.24 |
| Total Debt | 0.42 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 20.01 | 1.00 | 5.97 | 9.38 | 8.85 | 13.86 | 3.55 | 0.53 | 0.95 | 0.24 |
| Assets | 22.66 | 2.55 | 8.86 | 12.20 | 10.76 | 15.48 | 5.08 | 2.34 | 3.23 | 3.11 |
| Liabilities | 1.57 | 1.33 | 0.79 | 3.96 | 0.94 | 0.56 | 0.29 | 0.33 | 0.32 | 0.25 |
| Book Value | 21.09 | 1.22 | 8.07 | 8.24 | 9.82 | 14.92 | 4.78 | 2.01 | 2.91 | 2.86 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Bio-Path Holdings, Inc. |
| Country |
United States |
| Employees |
9 |
| CEO |
Peter H. Nielsen |
Stock Information
| Ticker Symbol |
BPTH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BPTH |
Description
Bio-Path Holdings operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.